SCHEMBL129669

SCHEMBL129669

O=C(O)c1cc(Br)ccc1O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.72
HPGD P15428 2/20 0.72
ALOX15 P16050 2/20 0.72
CASP1 P29466 2/20 0.72
CYP2C19 P33261 2/20 0.72
CES2 O00748 1/20 0.72
GALR3 O60755 1/20 0.72
CYP1A2 P05177 1/20 0.72
CA1 P00915 2/20 0.61
CA2 P00918 2/20 0.61
PTGS2 P35354 2/20 0.61
CA12 O43570 1/20 0.61
ALOX5 P09917 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
KDM4E B2RXH2 2/20 0.61
GLA P06280 1/20 0.61
GSTA1 P08263 1/20 0.60
MEN1 O00255 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30352763 1.00 CYP2C9 (0.72) CYP2C9HPGDALOX15CASP1CYP2C19
SCHEMBL9487167 0.98 CYP2C9 (0.69) CYP2C9HPGDALOX15CASP1CYP2C19
Acetic Acid SCHEMBL29404037 0.94 CYP2C9 (0.64) CYP2C9HPGDALOX15CASP1CYP2C19
Acetic Acid SCHEMBL25029 0.94 CYP2C9 (0.64) CYP2C9HPGDALOX15CASP1CYP2C19
1,4-Butanediol SCHEMBL11023193 0.89 CYP2C9 (0.58) CYP2C9HPGDALOX15CASP1CYP2C19
SCHEMBL29355897 0.84 CES2 (1.00) CYP2C9HPGDALOX15CASP1CYP2C19
SCHEMBL2156880 0.84 CES2 (1.00) CYP2C9HPGDALOX15CASP1CYP2C19
SCHEMBL15684683 0.84 ALOX15 (1.00) CYP2C9HPGDALOX15CASP1CYP2C19
SCHEMBL21812547 0.83 GSTA1 (0.77) CYP2C9HPGDALOX15CASP1CYP2C19
SCHEMBL467470 0.82 ALDH1A1 (0.61) CYP2C9HPGDALOX15CASP1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND KAO CORPORATION (JP) 2025-07-03 US claimed
CN-120082479-A Composite bacterium for biological strengthening and sludge reduction and preparation method thereof 无锡映川环境技术有限公司 2025-06-03 CN claimed
CN-120058783-A Preparation method and application of tris (2-methyl-2-phenylpropyl) tin 5-bromosalicylate complex 衡阳师范学院 2025-05-30 CN claimed
CN-120058781-A Preparation method and application of tricyclohexyltin 5-bromosalicylate complex 衡阳师范学院 2025-05-30 CN claimed
EP-4352449-B1 PROJECTILE PAYLOAD FOR TRAINING AMMUNITION WITH MULTI-SPECTRAL OUTPUT CYALUME TECH INC (US) 2025-05-07 EP claimed
CN-119684323-A Zinc complex and preparation method thereof 桂林师范高等专科学校 2025-03-25 CN claimed
EP-4501896-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND Kao Corporation (JP) 2025-02-05 EP claimed
CN-119308038-A Preparation method and application of photochromic dye modified spandex fiber 湖北省不挽离人科技有限公司 2025-01-14 CN claimed
CN-118619869-B Halogen-containing lithium ion eutectic crystal and preparation method and application thereof 佛山大学 2024-11-22 CN claimed
CN-118973990-A Process for producing cyclic diketone compound 花王株式会社 2024-11-15 CN claimed
US-4567019-A RAPID, REVERSIBLE THERMOCHROMISM GRAPHIC CONTROLS CORPORATION (US) 1986-01-28 US claimed
EP-0036145-B1 AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT INTERx RESEARCH CORPORATION (US) 1985-05-29 EP claimed
EP-0031561-B1 A RECTALLY ADMINISTERED SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT MERCK & CO. INC. (US) 1985-04-10 EP claimed
US-4470980-A Method of increasing oral absorption of β-lactam antibiotics INTERX RESEARCH CORP. (US) 1984-09-11 US claimed
US-4464363-A HYDROXY ARYL- OR HYDROXY ARALKYL ACIDS OR SALTS MERCK & CO., INC. (US) 1984-08-07 US claimed
US-4406896-A ANTIBIOTICS, ACIDS, HYDROXY MERCK & CO., INC. (US) 1983-09-27 US claimed
EP-0036534-A1 An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-30 EP claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
EP-0035770-A2 An orally administered drug form comprising a glycosidic antibiotic and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-16 EP claimed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214921-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND HSD17B7, HSD17B12, BCKDK CYP2C9 356/4885HPGD 441/4885ALOX15 400/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.